Innovfusion Pte. Ltd.

EPIVA improves epidural analgesia for labour pain

EPIVA Infusion Pump (Epidurals)

Innovfusion is excited to introduce EPIVA, a dedicated pump for epidural analgesia, a pain-relief technique used by over 50% of women in labour in developed countries. EPIVA features a modified technique that will improve epidural pain management for women.

Innovfusion is a medical devices company developing smarter infusion pump systems for administering and/or managing labour analgesia. The first pump, EPIVA, has a proprietary algorithm to anticipate patient pain and provide corresponding amounts of analgesia.

Currently-available infusion pump systems operate on a request basis, where patients receive a background infusion of analgesics with additional doses upon request. Though labour pain is known to intensify as labour progresses, present systems do not modulate background infusion rates. Some patients reported continuing episodes of “breakthrough” or unbearable pain, while others faced intense numbing of their lower limbs and had difficulty in the delivery process.

EPIVA features an improved algorithm that performs an hourly calculation of patient demand and modulates the background dose of analgesia accordingly. This algorithm is based on techniques developed at KK Women’s and Children’s Hospital, a leading maternity hospital in Singapore.

The technique has been validated in early trials with modified infusion pumps, where it recorded a significant decrease in episodes of breakthrough pain. Importantly, the technique increased maternal satisfaction and lowered physician intervention, though the volume of analgesic required remained the same.

Innovfusion is developing EPIVA as a dedicated system for anticipatory patient-controlled epidural analgesia. Additionally, EPIVA will have a robust construction enabling the delivery of high-pressure drug boluses into the epidural space. Boluses have been shown to achieve larger spreads in the epidural space, numbing more nerves for better epidural efficacy.

EPIVA will be launched in end-2014 for a 3,000-patient clinical trial in Singapore.